June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
CRISPR-Cas9 Mediated Genome Editing of Myocilin in Trabecular Meshwork Cells
Author Affiliations & Notes
  • Ankur Jain
    Pediatrics, Howard Hughes Medical Institute, Iowa City, IA
  • Gulab Zode
    Cell Biology and Immunology, North Texas Eye Research Institute, Fort Worth, TX
  • Charles Searby
    Pediatrics, Howard Hughes Medical Institute, Iowa City, IA
  • Abbot F Clark
    Cell Biology and Immunology, North Texas Eye Research Institute, Fort Worth, TX
  • Val C Sheffield
    Pediatrics, Howard Hughes Medical Institute, Iowa City, IA
  • Footnotes
    Commercial Relationships Ankur Jain, None; Gulab Zode, None; Charles Searby, None; Abbot Clark, None; Val Sheffield, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3187. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ankur Jain, Gulab Zode, Charles Searby, Abbot F Clark, Val C Sheffield; CRISPR-Cas9 Mediated Genome Editing of Myocilin in Trabecular Meshwork Cells. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3187.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Glaucoma is a leading cause of irreversible blindness with elevated intraocular pressure (IOP) being the most important risk factor. Mutations in myocilin (MYOC) leading to MYOC misfolding and increased expression of MYOC by dexamethasone (DEX) have been associated with endoplasmic reticulum (ER) stress in the trabecular meshwork (TM), the tissue that maintains the aqueous humor outflow and regulates IOP. ER stress and/or death of the TM lead to ocular hypertension and glaucoma. We propose to relieve ER stress in human and mouse TM cells by targeting the MYOC gene using state of art CRISPR-Cas9 technology.

Methods: We generated TM cell lines overexpressing wild type and mutant human MYOC and looked for ER stress markers using quantitative PCR and western immunoblotting. MYOC was targeted by transient transfection of px330-CRISPR plasmids with guide RNAs targeting the MYOC gene (Exon1). Mouse TM cells were pretreated with Ad5px330-CRISPR virus and checked for DEX-mediated MYOC accumulation and ER stress.

Results: TM cell lines overexpressing mutant MYOC have increased accumulation of MYOC in the ER and increased ER stress as compared to wild type. Transient transfection reduces levels of MYOC and ER stress in these cells. Mouse TM cells have reduced levels of DEX-mediated ER stress when pretreated with Ad5-CRISPR as compared to null virus controls.

Conclusions: This is a proof of principle study indicating that targeting the MYOC gene can relieve ER stress in TM cells, rescuing their function. We plan to translate this approach to in vivo transgenic hMYOCY437H and DEX-induced ocular hypertension mouse models.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×